Table 2.

Changes in the updated consensus statement

Section	Update in 2016 statement
CTCL	It is recommended that the treatment schedule may be continued in patients with a complete, partial or minimal response as opposed to treatment taper. This is in keeping with other treatments for advanced MF/SS, which should be continued whilst a clinical benefit is derived and cessation of therapy is not recommended whilst a response is durable. This is because there are no curative therapies for CTCL and, in some patients, durable responses >5 years are shown with ECP, which is markedly improved compared to the median survival of advanced stage patients around 3 years (Appendix S2)
Acute GvHD	New section, with recommendations on patient selection, treatment schedule, assessment criteria and steroid taper (Appendix S3). Literature review updated to include adults and paediatrics
Chronic GvHD	Update to assessment of response using National Institutes of Health criteria (Lee et al, 2015) – Appendix S4
Solid organ transplantation	New section on the use of ECP in solid organ transplantation
Technical considerations	New section with the use of closed system CELLEX (Therakos, Exton, PA USA), significantly shortening treatment times, allowing double needle access and treatment of lower body weight patients (<40 kg) low body weight is no longer an exclusion criteria Update on technical aspects of administration of ECP, including complications and their management (Appendix S5)
Quality management	New section setting out a modular Quality Assurance programme (Appendix S6)

CTCL, cutaneous T‐cell lymphoma; ECP, extracorporeal photopheresis; GvHD, graft‐versus‐host disease; MF, mycosis fungoides; SS, Sézary syndrome.